Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 4/2019

16.08.2018 | Original Research

Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients

verfasst von: Yanshuo Cao, Qing Chang, Michael Cabanero, Wenjiang Zhang, Sara Hafezi-Bakhtiari, David Hedley, Gail Darling, Fayez Quereshy, Raymond Jang, Elena Elimova, Jennifer Knox, Olga Ornatsky, Stefano Serra, Eric Chen

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is a wide range in tumor response following preoperative chemotherapy in locally advanced gastric or gastroesophageal junction cancers. We investigated the relationship between tumor platinum levels and pathological responses in these patients.

Methods

Tumor and adjacent normal tissues were retrieved. Pathological responses were assessed per standard criteria. Tissue platinum concentrations were determined with high-performance liquid chromatography mass spectrometry. Platinum distribution in tissue components was evaluated with imaging mass cytometry. Collagen content was evaluated using trichrome staining.

Results

Surgical specimens from 10 patients were available. Surgery was performed at a median time of 49 days (range: 28–72) after the last cycle of chemotherapy. The mean platinum level in tumor tissue in patients with any response was significantly higher than in those with no response (893 ± 460 vs. 38.8 ± 8.8 pg, P = 0.007), so was the collagen content (37.4 ± 6.8 vs. 11.5 ± 8.6%, P < 0.05). Platinum preferentially bound to collagen.

Conclusions

Platinum was detectable in surgical specimens up to 72 days after preoperative chemotherapy. Higher tumor platinum concentration correlated with improved pathological response. Collagen binding potentially explained the high interpatient variability in tumor platinum concentrations.
Literatur
3.
Zurück zum Zitat Al-Batran S-E, Homann N, Schmalenberg H, Kopp H-G, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35:4004. https://doi.org/10.1200/JCO.2017.35.15_suppl.4004.CrossRef Al-Batran S-E, Homann N, Schmalenberg H, Kopp H-G, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35:4004. https://​doi.​org/​10.​1200/​JCO.​2017.​35.​15_​suppl.​4004.CrossRef
8.
Zurück zum Zitat (June 2014). College of American Pathologists Protocol for the Examination of Specimens From Patients With Carcinoma of the Stomach Version: Stomach 3.3.0.0. (June 2014). College of American Pathologists Protocol for the Examination of Specimens From Patients With Carcinoma of the Stomach Version: Stomach 3.3.0.0.
10.
Zurück zum Zitat Goldner J. A modification of the masson trichrome technique for routine laboratory purposes. Am J Pathol. 1938;14:237–43.PubMedPubMedCentral Goldner J. A modification of the masson trichrome technique for routine laboratory purposes. Am J Pathol. 1938;14:237–43.PubMedPubMedCentral
13.
Zurück zum Zitat Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Mumtaz E, et al. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. J Surg Oncol. 2017;115:821–9. https://doi.org/10.1002/jso.24601.CrossRefPubMed Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Mumtaz E, et al. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. J Surg Oncol. 2017;115:821–9. https://​doi.​org/​10.​1002/​jso.​24601.CrossRefPubMed
16.
Zurück zum Zitat Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990;2:35–43.PubMed Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990;2:35–43.PubMed
18.
Zurück zum Zitat Imamura T, Iguchi H, Manabe T, Ohshio G, Yoshimura T, Wang ZH, et al. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas. 1995;11:357.CrossRefPubMed Imamura T, Iguchi H, Manabe T, Ohshio G, Yoshimura T, Wang ZH, et al. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas. 1995;11:357.CrossRefPubMed
Metadaten
Titel
Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients
verfasst von
Yanshuo Cao
Qing Chang
Michael Cabanero
Wenjiang Zhang
Sara Hafezi-Bakhtiari
David Hedley
Gail Darling
Fayez Quereshy
Raymond Jang
Elena Elimova
Jennifer Knox
Olga Ornatsky
Stefano Serra
Eric Chen
Publikationsdatum
16.08.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 4/2019
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0153-9

Weitere Artikel der Ausgabe 4/2019

Journal of Gastrointestinal Cancer 4/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.